Connaughton Bernadette 4

What Happened
Bernadette Connaughton, a director of Editas Medicine (EDIT), was granted an award of 51,700 derivative shares (reported as an option/award) on June 17, 2026. The Form 4 reports an acquisition price of $0.00 (award/derivative), and the grant is scheduled to vest in full on June 17, 2027. This was a compensation award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-17 (Form 4 filed: 2026-06-22).
• Transaction type/code: A (Award/Grant of derivative shares). Reported price: $0.00 (derivative award).
• Shares/units granted: 51,700 (derivative security).
• Vesting: Grant vests in full on 2027-06-17 (see footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Filed 6/22/2026 for a 6/17/2026 grant — this appears later than the usual 2-business-day Form 4 deadline, reducing short-term transparency.

Context

• This is a grant of a derivative (likely stock options or restricted stock units) as director compensation; it is not an immediate cash purchase or sale and does not necessarily indicate a near-term buy/sell decision.
• For derivative awards, the recipient typically must wait for vesting (here, one year) before the award converts to exercisable/owned shares; any exercise or sale would be reported separately.
• Grants to directors are common as part of compensation packages; retail investors should note the vesting schedule and watch for later filings if the award is exercised or shares are sold.